CD19 and leukemia: compared the FMC63 (high-affinity) and CAT (moderate-affinity) CD19 CARTs and found that, after engaging with CD19+ leukemia cells, the CAT CD19 CARTs contained significantly more polyfunctional T cells than the FMC63-derived CARTs (160).